Beckman Coulter introduces antipsychotic drug testing to address unmet clinical need for more than 69m people living with serious mental conditions

Beckman Coulter, a global clinical diagnostics leader, will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide.

In a new agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the tests designed to measure blood levels of antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as Schizophrenia and Bipolar Disorder. These new assays are developed using an innovative nanoparticle technology and empower healthcare professionals with data to monitor psychiatric drugs prescribed in treatment of psychosis: Clozapine, Risperidone/Paliperidone, Olanzapine, Quetiapine, Aripiprazole.

The rapid, high-quality assays run on Beckman Coulter’s scalable AU clinical chemistry analysers and shorten turnaround time for patient test results to hours instead of days – leading to greater success managing and monitoring treatments for inpatients and outpatients.

Serious mental illness is a significant public health concern. Worldwide 45 million people are affected by bipolar disorder and 24 million people are living with schizophrenia. Patients with untreated schizophrenia or bipolar may experience increased intensity of symptoms which could be disabling, potentially resulting in additional medical care or could lead to suicide. These new assays assist healthcare professionals to evaluate patient treatment adherence and individual patient drug response.

Kathleen Orland, senior vice president & general manager, clinical chemistry and immunoassay, Beckman Coulter, says: “Beckman Coulter’s portfolio of therapeutic drug monitoring assays offers laboratories and diagnostic testing facilities ways to improve patient care by ensuring therapeutic ranges are monitored. Our relationship with Saladax expands access for laboratories and clinicians to antipsychotic drug testing for treatment of psychotic disorders, which is a growing healthcare need.”

Sal Salamone, CEO and founder, Saladax, says: “Our partnership with Beckman Coulter is a major step in making these important antipsychotic tests available to healthcare professionals. These tests provide timely quantitative insights so they can make reliable assessments that will improve the care of patients with serious mental illness.”

Assays are being introduced across Europe and the US, with plans to expand to Beckman Coulter customers globally. For more information about Beckman Coulter’s Antipsychotic Drug Testing addition to Therapeutic Drug Monitoring, visit

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news